Intellectual Property India Publishes Patent Application for Combination Therapy Involving Bispecific Binding Agents Binding To Cldn18.2 And Cd3 And Anti- Vegfr2 Antibodies

MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202647069481 A) filed by Astellas Pharma Inc. on June 03, 2026, for Combination Therapy Involving Bispecific Binding Agents Binding To Cldn18.2 And Cd3 And Anti- Vegfr2 Antibodies.

Inventors include Nakano, Kazue; and Nakazawa, Taisuke.

The application for the patent was published on June 12, 2026, under issue no. 24/2026.

Abstract: The present invention provides a combination therapy involving bispecific binding agents comprising two binding domains binding to CLDN18.2 and a binding domain binding to CD3 and antibodies that binds to VEGFR2. The combination therapy is effective in treating cancer involving cancer cells expressing CLDN18.2.

Disclaimer: Curated by HT Syndication.